FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097890489> ?p ?o ?g. }

• W3097890489 endingPage "1015" @default.
• W3097890489 startingPage "996" @default.
• W3097890489 abstract "Resistance to anoikis, cell death due to matrix detachment, is acquired during tumor progression. The 14-3-3σ protein is implicated in the development of chemo- and radiation resistance, indicating a poor prognosis in multiple human cancers. However, its function in anoikis resistance and metastasis in hepatocellular carcinoma (HCC) is currently unknown. Methods: Protein expression levels of 14-3-3σ were measured in paired HCC and normal tissue samples using western blot and immunohistochemical (IHC) staining. Statistical analysis was performed to evaluate the clinical correlation between 14-3-3σ expression, clinicopathological features, and overall survival. Artificial modulation of 14-3-3σ (downregulation and overexpression) was performed to explore the role of 14-3-3σ in HCC anoikis resistance and tumor metastasis in vitro and in vivo. Association of 14-3-3σ with epidermal growth factor receptor (EGFR) was assayed by co-immunoprecipitation. Effects of ectopic 14-3-3σ expression or knockdown on EGFR signaling, ligand-induced EGFR degradation and ubiquitination were examined using immunoblotting and co-immunoprecipitation, immunofluorescence staining, and flow cytometry analysis. The levels of EGFR ubiquitination, the interaction between EGFR and 14-3-3σ, and the association of EGFR with c-Cbl after EGF stimulation, in 14-3-3σ overexpressing or knockdown cells were examined to elucidate the mechanism by which 14-3-3σ inhibits EGFR degradation. Using gain-of-function or loss-of-function strategies, we further investigated the role of the EGFR signaling pathway and its downstream target machinery in 14-3-3σ-mediated anoikis resistance of HCC cells. Results: We demonstrated that 14-3-3σ was upregulated in HCC tissues, whereby its overexpression was correlated with aggressive clinicopathological features and a poor prognosis. In vitro and in vivo experiments indicated that 14-3-3σ promoted anoikis resistance and metastasis of HCC cells. Mechanistically, we show that 14-3-3σ can interact with EGFR and significantly inhibit EGF-induced degradation of EGFR, stabilizing the activated receptor, and therefore prolong the activation of EGFR signaling. We demonstrated that 14-3-3σ downregulated ligand-induced EGFR degradation by inhibiting EGFR-c-Cbl association and subsequent c-Cbl-mediated EGFR ubiquitination. We further verified that activation of the ERK1/2 pathway was responsible for 14-3-3σ-mediated anoikis resistance of HCC cells. Moreover, EGFR inactivation could reverse the 14-3-3σ-mediated effects on ERK1/2 phosphorylation and anoikis resistance. Expression of 14-3-3σ and EGFR were found to be positively correlated in human HCC tissues. Conclusions: Our results indicate that 14-3-3σ plays a pivotal role in the anoikis resistance and metastasis of HCC cells, presumably by inhibiting EGFR degradation and regulating the activation of the EGFR-dependent ERK1/2 pathway. To our best knowledge, this is the first report of the role of 14-3-3σ in the anoikis resistance of HCC cells, offering new research directions for the treatment of metastatic cancer by targeting 14-3-3σ." @default.
• W3097890489 created "2020-11-09" @default.
• W3097890489 creator A5003556148 @default.
• W3097890489 creator A5022473653 @default.
• W3097890489 creator A5043910391 @default.
• W3097890489 creator A5044757881 @default.
• W3097890489 creator A5057454191 @default.
• W3097890489 creator A5062858717 @default.
• W3097890489 creator A5076716729 @default.
• W3097890489 creator A5077653640 @default.
• W3097890489 creator A5079739556 @default.
• W3097890489 creator A5081108200 @default.
• W3097890489 creator A5088666593 @default.
• W3097890489 creator A5090031066 @default.
• W3097890489 creator A5091070290 @default.
• W3097890489 date "2021-01-01" @default.
• W3097890489 modified "2023-10-16" @default.
• W3097890489 title "The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway" @default.
• W3097890489 cites W1581920763 @default.
• W3097890489 cites W1608422721 @default.
• W3097890489 cites W166052832 @default.
• W3097890489 cites W1925416510 @default.
• W3097890489 cites W1967703311 @default.
• W3097890489 cites W1969909442 @default.
• W3097890489 cites W1971663925 @default.
• W3097890489 cites W1975315649 @default.
• W3097890489 cites W1980217369 @default.
• W3097890489 cites W1983445012 @default.
• W3097890489 cites W1983821491 @default.
• W3097890489 cites W1985356509 @default.
• W3097890489 cites W1987062501 @default.
• W3097890489 cites W1994927207 @default.
• W3097890489 cites W2000913350 @default.
• W3097890489 cites W2001126978 @default.
• W3097890489 cites W2003867647 @default.
• W3097890489 cites W2003935051 @default.
• W3097890489 cites W2004759810 @default.
• W3097890489 cites W2013051283 @default.
• W3097890489 cites W2033028443 @default.
• W3097890489 cites W2033608521 @default.
• W3097890489 cites W2045649656 @default.
• W3097890489 cites W2048326719 @default.
• W3097890489 cites W2049329312 @default.
• W3097890489 cites W2054736529 @default.
• W3097890489 cites W2056893202 @default.
• W3097890489 cites W2059493866 @default.
• W3097890489 cites W2063626023 @default.
• W3097890489 cites W2067045583 @default.
• W3097890489 cites W2075000266 @default.
• W3097890489 cites W2075956249 @default.
• W3097890489 cites W2091823826 @default.
• W3097890489 cites W2097085745 @default.
• W3097890489 cites W2100233587 @default.
• W3097890489 cites W2104050632 @default.
• W3097890489 cites W2104738007 @default.
• W3097890489 cites W2106787323 @default.
• W3097890489 cites W2121589581 @default.
• W3097890489 cites W2123340475 @default.
• W3097890489 cites W2134609748 @default.
• W3097890489 cites W2137052325 @default.
• W3097890489 cites W2138362890 @default.
• W3097890489 cites W2139656426 @default.
• W3097890489 cites W2140009101 @default.
• W3097890489 cites W2152171710 @default.
• W3097890489 cites W2159582103 @default.
• W3097890489 cites W2160926271 @default.
• W3097890489 cites W2165200432 @default.
• W3097890489 cites W2572164705 @default.
• W3097890489 cites W2572183431 @default.
• W3097890489 cites W2611129083 @default.
• W3097890489 cites W2745216110 @default.
• W3097890489 cites W2783117838 @default.
• W3097890489 cites W2949213103 @default.
• W3097890489 cites W2992784349 @default.
• W3097890489 doi "https://doi.org/10.7150/thno.51646" @default.
• W3097890489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7738881" @default.
• W3097890489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33391517" @default.
• W3097890489 hasPublicationYear "2021" @default.
• W3097890489 type Work @default.
• W3097890489 sameAs 3097890489 @default.
• W3097890489 citedByCount "35" @default.
• W3097890489 countsByYear W30978904892021 @default.
• W3097890489 countsByYear W30978904892022 @default.
• W3097890489 countsByYear W30978904892023 @default.
• W3097890489 crossrefType "journal-article" @default.
• W3097890489 hasAuthorship W3097890489A5003556148 @default.
• W3097890489 hasAuthorship W3097890489A5022473653 @default.
• W3097890489 hasAuthorship W3097890489A5043910391 @default.
• W3097890489 hasAuthorship W3097890489A5044757881 @default.
• W3097890489 hasAuthorship W3097890489A5057454191 @default.
• W3097890489 hasAuthorship W3097890489A5062858717 @default.
• W3097890489 hasAuthorship W3097890489A5076716729 @default.
• W3097890489 hasAuthorship W3097890489A5077653640 @default.
• W3097890489 hasAuthorship W3097890489A5079739556 @default.
• W3097890489 hasAuthorship W3097890489A5081108200 @default.
• W3097890489 hasAuthorship W3097890489A5088666593 @default.
• W3097890489 hasAuthorship W3097890489A5090031066 @default.
• W3097890489 hasAuthorship W3097890489A5091070290 @default.

• next